Evaxion Reports Final Dose Administered in Phase 2 EVX-01 Personalized Cancer Vaccine Trial

Evaxion Biotech A/S, a company at the forefront of AI-Immunology™, has reached a significant milestone in its Phase 2 clinical trial for the EVX-01 vaccine. The trial, which began in September 2022, is designed to evaluate the vaccine's efficacy, safety, and immune response in patients with metastatic melanoma. The vaccine is tailored to each patient's unique tumor profile and immune system characteristics, representing a personalized approach to cancer treatment.

The first patient in the trial has completed the final dosing of the vaccine, which is administered alongside KEYTRUDA® (pembrolizumab), an anti-PD-1 therapy. This marks a promising step forward in the development of individualized cancer vaccines. The vaccine's safety profile has been confirmed as favorable, and the trial is progressing smoothly towards a one-year clinical efficacy readout expected in the third quarter of 2024.

Evaxion's Chief Scientific Officer, Birgitte Rønø, expressed optimism about the progress, stating that the company is closer to its mission of improving lives through AI-Immunology™. The upcoming clinical readout is eagerly anticipated, as it could bring the innovative personalized cancer vaccine closer to market availability.

Professor Adnan Khattak from One Clinical Research in Western Australia highlighted the significance of the trial, emphasizing the move towards personalized cancer therapies that target each patient's tumor with precision. He believes this tailored approach represents the future of cancer treatment.

Evaxion's EVX-01 vaccine is a peptide-based personalized cancer vaccine, and the Phase 2 study is an open-label, single-arm, multi-center trial in collaboration with Merck Sharp & Dohme LLC. It involves leading investigators and research centers from Italy and Australia, aiming to assess the vaccine's efficacy and safety in combination with KEYTRUDA® for patients with metastatic or unresectable stage III or IV melanoma.

Evaxion Biotech A/S is a pioneering TechBio company that leverages its AI platform to decode the human immune system and develop new immunotherapies for various diseases. The company's AI-Immunology™ platform has led to a clinical-stage oncology pipeline of personalized vaccines and a preclinical pipeline for infectious diseases with significant unmet medical needs. Evaxion is dedicated to transforming patient care through innovative and targeted treatment options.